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ABSTRACT  
Aim 
To identify the most crucial interval to encourage earlier diagnosis in with gastroesophageal 
cancer and to identify potential factors effecting this interval.  
Background  
Gastroesophageal malignancy is the eighth most commonly presenting cancer with one of the 
worst survival rates. Identifying the most crucial period for intervention to inform earlier 
diagnosis is an important step towards improving survival.  
Design  
Mixed methods literature review. 
Data Sources  
CINAHL, MEDLINE and Academic search primer online databases were searched using 
keywords and inclusion/exclusion criteria. Empirical evidence published between 2000- 2016 
with a focus on gastroesophageal cancer presentation and survival was reviewed to inform this 
study.  
Review methods  
Twelve studies were extracted for further review. Selected studies were appraised and 
presented through Olensen’s ‘delay interval’ framework to inform the most crucial interval to 
survival in GOC.  
Results  
The findings identify the patient interval as the most critical period for encouraging earlier 
presentation and reducing advanced stage presentation in gastroesophageal cancer. The article 
also highlighted some methodological limitations to cancer research, such as a lack of 
consensus in definitions which prevent statistical meta-analysis of cancer data, survivor bias in 
gastroesophageal cancer studies and a significant lack of qualitative evidence to reveal patient 
experience in presenting with this cancer.  
Conclusion 
Further research into the patient interval is required to elicit information on how and why 
patients present with their cancer symptoms.  
Keywords  
cancer, interval delay, oesophagogastric cancer, cancer data, advanced presentation, late 
presentation, literature review methodology, cancer methodology, GOC, early presentation 
  
Summary statement  
Why is this review required?  
Internationally, there is a wide variety in presentation and survival in gastroesophageal cancer. 
This paper reviews evidence from several countries on presentation and survival, to identify 
the most crucial stage for intervention. It exposes the diverse range of timelines and 
nomenclature commonly used and reveals how these can affect findings in gastroesophageal 
cancer research. This paper presents these findings so that nurses can make informed decisions 
to deliver more targeted clinical interventions in the drive to encourage earlier diagnosis. 
What are the key findings?  
 This is the first study to reveal patient interval as the most crucial stage to survival in 
gastroesophageal cancer  
 The incidence of gastroesophageal cancer is increasing but compared with other 
cancers, it is relatively overlooked.  
 There is significant variation in how cancer survival and presentation is analysed and 
assessed. The disparate nomenclature needs closer review to ascertain meaningful 
results.  
How should findings be used to influence policy/practice/research/education?  
 Further evidence is required on patient level factors affecting presentation.  
 Potential cancer patients need to be encouraged to seek treatment earlier.  
 There is a need to standardise timeframes and definitions in early diagnosis cancer 
research.  
  
Introduction  
Gastroesophageal cancer (GOC) is a common cancer with a high morbidity and mortality rate. 
This systematic literature review of empirical evidence presents a narrative synthesis of 
evidence to identify the most crucial stage to encouraging earlier diagnosis. It also discusses 
the methodological limitations in cancer research. The findings are relevant to any cancer 
because earlier diagnosis is essential to survival. Knowing which interval is key in improved 
survival can guide further research and a more targeted clinical intervention. 
Background  
Gastroesophageal cancer (GOC) has an extremely high mortality and very low predicted 
survival rate following diagnosis (Adair et al., 2011; Allum et al., 2002; NHS 2008; Nuting et 
al., 2008; Office for National Statistics, 2005; Orengo et al., 2006; Sloggett et al., 2007;  Zheng 
et al., 2010; Medical research Council, 2002; National Institute for Health and Clinical 
Excellence, 2005). GOC patients often present at an advanced stage, meaning tumours are 
infiltrated to such an extent that surgical cure is not possible. A recent meta-analysis of 
literature identified that an increased time to diagnosis is highly associated with a poor outcome 
and that advanced stage presentation is a major concern in many cancers (Neal et al., 2015)  
Given the recently published guidelines seeking to clarify the range of definitions and 
timescales applied in early cancer research (Weller et al, 2012), a structured analysis of 
literature related to advanced presentation GOC is both timely and appropriate. This is the first 
systematic literature review specifically to focus on advanced stage GOC since the publication 
of Weller et al’s (2012) ‘Aarhus checklist’. The Aarhus checklist offers a tool to address the 
lack of consistency in definitions applied in early cancer diagnosis research. It is applied in this 
narrative synthesis of evidence as an adjunct to CASP for quality appraisal.  
 
The Review  
Aim  
The aim of this review was to identify the most crucial interval for earlier diagnosis 
interventions and to identify common factors linked with advanced presentation. Objectives of 
this study were to: 
 Undertake critical evaluation of all evidence evaluating presentation stage and survival 
in GOC.  
 Present a narrative synthesis of evidence through Olenssen’s ‘delay interval 
framework’.  
 Use the main characteristics and attributes linked with the delay periods to make 
recommendations for further study into early diagnosis.  
Design  
The York Centre for Reviews and Dissemination guidelines handbook (2009) was used to 
underpin a mixed method systematic review. Results of the initial search were structured using 
the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) statement. 
The most recent (2015) PRISMA guidance was adopted (Liberati et al., 2009; Moher, Liberati, 
Tetzlaff, & Altman, 2009; Moher et al., 2015; Shamseer et al., 2015). PRISMA is an effective 
and widely accepted tool in the standardisation of the information retrieval processes (Moher 
et al., 2015). For quality appraisal, relevant tools were taken from the Critical Appraisal Skills 
Programme (CASP), adapted to incorporate the Aarhus checklist for early diagnosis research. 
As there is a distinct lack of consensus in definitions of diagnosis and staging in the literature, 
results are presented as a narrative synthesis, through Olenssen’s delay interval framework 
(Figure 1).  
Search methods  
A systematic literature search was undertaken for any papers published from 2000 - 2014 
available through CINAHL, Medline, Psychinfo, EBSCOHOST and Academic Search Primer. 
This date range built on evidence available following Macdonald’s seminal systematic review 
on upper gastrointestinal cancers in 2006 (Macdonald et al., 2006). The UK clinical research 
network had two relevant studies in progress, but no published results to date. The National 
Research Register and NIHR clinical trials gateway revealed no current trials on advanced 
stage presentations in cancers. Discussions with Cancer Research Charities UK and the Cancer 
Research (gastroesophageal group) network identified only one study protocol at an initial 
phase, so no results were available. Referenced citations were reviewed and followed up to 
identify any further studies of significance to this methodology.  
Eligibility and study selection  
Several frameworks exist to assist the process of structuring a research question (PICOs and 
PICo (JBI, 2014), MIP (Stretch et al, 2008) and SPIDER (Cooke, 2012). As the aim of this 
review was to identify the most crucial stage for interventions to encourage earlier presentation 
with GOC, PICo was used (Figure 2) to identify population, phenomena of interest and the 
context where the phenomena occurred (JBI, 2014). The research question was  
Which interval is most crucial to encourage earlier presentation and improved survival in 
gastroesophageal cancer?  
Explicit inclusion and exclusion criteria supported retrieval of relevant studies. Defining the 
population as all patients with a histological confirmation of gastroesophageal cancers provided 
a strict exclusion criteria. The phenomena of interest were any factors which had an impact on 
patient survival outcomes. Therefore, any studies which included patient doctor or service level 
interventions, survival analysis and, or revealing potential delays in the diagnostic journey were 
included. Studies without specific GOC focus were omitted from this review.  
Studies conducted in any country were included, which were published in the English language. 
Dates were limited to studies published after 2000 only to maintain clinical and temporal 
relevance commensurate with improvements in care and treatments. Papers not meeting initial 
methodological scrutiny were discussed with co-authors. These were rejected through 
consensus opinion.  
A Boolean search strategy of CINAHL, MEDLINE and Academic search primer yielded 12 
papers. Synonyms and specific expressions for this were drawn from an initial scoping database 
review. MeSH terms are identified online (table 1) (available online via http address). Only 
empirical studies from peer reviewed scholarly journals were selected. 
Data abstraction  
The search strategy is presented in the PRISMA flow diagram (Figure 3). All papers focusing 
on treatment modalities or that were not GOC specific were rejected. After duplicates were 
removed, abstracts were reviewed. Those meeting inclusion criteria and addressing the research 
question were chosen for further analysis. Of these 24, a total of 15 empirical papers were 
selected for critique based on methodological rigour, appropriateness to the research question 
and definition of timescales. One audit detailing GOC incidence in the UK was appropriate to 
the review.  
In general, most studies were retrospective reviews of cancer registry data (survival studies), 
or single centre cohort studies. The national registry data studies focused on events, survival 
and times and had large datasets (overall n = 26445 mean = 6611; median = 1507). The single 
centre cohort studies sought to explore factors which may be associated with any delays but 
relied on smaller numbers (n=48-491). There were two previous systematic reviews and a GP 
audit which either merged GOC with other cancers, or focused on factors associated with delay 
which were relevant to the discussion.  
Quality Appraisal  
This study included mainly cohort studies and papers on survival outcomes, so the appropriate 
CASP tool was applied to appraise results. Crowe and Sheppard (2011) have highlighted 
problems with having to access a range of different tools to appraise evidence on a single 
research question. They highlighted a need to apply a rigorous approach to appraising quality 
of evidence. Though the CASP tool for cohort studies encourages analysis of validity, results 
and local application, it is a generalised tool. Therefore, the Aarhus checklist was also applied 
to supplement and score papers under review. Using this checklist, scores were applied to how 
researchers had defined time points and intervals and which measurement and analytical tools 
had been used to underpin the research. These were found to vary significantly throughout the 
presented evidence. An online table (2) identifies how quality appraisal was applied to each 
study (http//www.) and an additional table (3) presents information on the appraisal outcome 
for each domain.  
All papers were initially assessed by the primary researcher and results agreed through 
consensus opinion between co-authors who consisted of a professor of nursing and a 
gastroenterology medical specialist. Where two researchers disagreed, the third was consulted 
and the evidence discussed until consensus was reached. 
Data synthesis  
Results were conceptually mapped to Olennsen’s delay intervals. This was used to identify the 
most crucial period for study into early diagnosis. This theoretical approach allows data to be 
presented through pre-determined themes which are drawn from the studies which have been 
selected (Braun and Clarke, 2006; Dixon-Woods et al, 2006). Results of the multiple studies 
were assimilated into a data extraction form which incorporated both CASP and Aarhus 
checklist components. 
  
RESULTS  
A total of 3839 records was extracted and narrowed following initial abstract review to 25 full 
length papers which were assessed for eligibility (Figure 1). From these 25 full text reviews, 
12 papers were chosen for further analysis and quality appraisal. The search strategy revealed 
a significant lack of available evidence with sole focus on gastroesophageal cancer and delays 
in the diagnostic journey. Much of the research evaluated efficacy of treatment or survival 
outcomes but did not apportion the specific time of delay. Table 3 presents a summary of 
studies included alongside their quality appraisal results.  
Studies which cover the total delay interval  
Six studies presented in this review presented findings across all the delay intervals. Bus et al 
(2013) presented a study on 1, 3 and 5-year survival in GOC, from which factors relating to 
presentation may be drawn. Their data analysis reflected Coupland et al’s (2012) methodology 
of retrospective analysis of cancer registry data. Bus et al (2013) revealed patients presenting 
with limited lymph node involvement had improved survival outcomes. They also revealed 
gender and absence of comorbidities was linked with increased survival. Numbers of subjects 
within the 1, 3 and 5 year cohorts were 703, 551 and 436 respectively, so the study was large. 
As with the UK, cancer notification is mandatory in the Netherlands, so there were no 
omissions from the dataset. The study relied on older data for survival analysis (some of these 
data were 24 years old at the time of publication) and this can only reflect the treatments 
available at that time. However, the study showed the ability to treat with curative intent 
increased survival significantly. Presentation at later stages and with comorbidities 
significantly reduced survival outcomes. Advancing age was not linked with impaired survival 
for those in the three year and the 5-year groups, but it was significant in those people dying 
before 1 year. They did not undertake further analysis with histological subtypes, but found a 
wide disparity in survival between different treatments (surgery, neoadjuvant therapy) and the 
extent of tumour infiltration and lymph node involvement at presentation, concluding that the 
earlier patients present with their GOC, the more likely they are to survive.  
Coupland et al’s (2012) research focussed on GOC diagnosis across the UK. A sample of 
13,3804 GOC diagnosed patients between 1998 - 2007 were analysed in relation to presentation 
and survival. This study revealed over half of middle and upper GOC were in females. This 
contradicts the usual 3:2 ratio of male to female GOC which is prevalent in the mainstay of 
GOC literature. The study also highlighted differences in survival relating to age, 
socioeconomic deprivation and stage of disease and called for further research into these 
factors. The authors conclude that early diagnosis is crucial to survival and encourage further 
studies to encourage earlier presentation, referrals and treatment.  
In the US, cancer registry data are handled differently. Hence more reliance on single centre 
studies, or state led studies which focus on private or public held datasets. A single centre study 
in the United States of America by Hashemi et al’s (2009) compared age groups and survival 
in 242 patients presenting between 1994 and 2004. They found younger patients tended to have 
higher lymphatic spread, but similar survival outcomes. Advanced stage presenters had worse 
outcomes, suggesting that the patient interval is crucial to survival.  
Another Netherlands study – this time by Groentihaus et al. (2010) revealed the impact of pre 
hospital and hospital delays on survival. They identified that late onset of symptoms often 
predisposes a delay in presentation, but this study also identified a shorter gap from diagnosis 
to treatment significantly improved survival outcomes. The recommendations from this single 
centre cohort study of 491 patients presenting between the years 1991 and 2007 were on 
reduction of patient and hospital delays and expedition of treatment.  
In Malaysia, Abdullah et al (2010) studied 143 patients presenting between 1998 and 2003, 
identified most patients in Malaysia present at very advanced stages and had very low survival 
outcomes. They also found a strong incidence in those from lower socioeconomic groups. This 
study was limited through its geography and over 71% of subjects presented at TNM stage iv. 
These statistics are very different to those in the Western World, so results may not be 
commensurate with local settings. However, the study does highlight the problem of patients 
not detecting symptoms early enough and that GOC survival is impaired at the patient interval. 
With a similar demographic profile, Alimoggadam et al’s (2014) retrospective analysis of 368 
medical notes revealed that patients with oesophageal and gastric cancer presented with very 
late staged GOC.  
Studies with focus on the patient interval  
Five studies presented data relating to advanced stage presentation which could be linked to 
the patient interval. Subasinghe et al (2010) undertook a 24 month study of patients presenting 
to a regional centre in Sri Lanka to review where delays may occur in the patient journey. They 
identified three periods. These were the time from patient first detecting symptoms, to first 
contact with the health service; first contact to endoscopy; endoscopy to histological 
confirmation. The study identified the patient interval (first symptom recognition to contact 
with health department), accounted for 82.2% of the delays, compared with doctor and system 
level intervals. However, as with the Malaysian study by Abdullah et al (2010), the ability to 
generalise findings to a Western context is potentially hampered by the differences in health 
provision in these countries. Subasinghe et al (2010) acknowledge the lack of available 
resources for histology and endoscopy and the limited health systems in Sri Lanka. There is no 
elaboration on how data were collected to determine the first symptom detection and the 
authors present no information on timing of patient interviews and triangulation of self-
reported data. There is no reference made to any tools which were applied to elicit information 
from patients and the authors have not elaborated on methodological approaches for data 
analysis. Their descriptive analysis of the cohort is different to the norm, as gender ratio was 
1:1 in this study.  
A single centre retrospective evaluation of patient notes in America by Schlansky et al (2006) 
presented data on tumour stage and presentation symptoms in patients with gastroesophageal 
cancer. Only subjects who had undergone oesophagogastroduodenoscopies who had not been 
previously diagnosed or treated for GOC were reviewed to reveal disease characteristics and 
patterns of diagnosis. They found the majority of presentations were staged at T3 or above, 
revealing a large patient interval delay. The study is somewhat limited through reliance on 
patient notes to elicit data on clinical symptoms at presentation.  
Another American single centre study by Gibbs et al (2007) provided evidence from a 
retrospective analysis of 307 GOC patients who presented between the years 1991 to 1996. 
They acknowledge their data is based on subjective patient response on when symptoms were 
initially detected, but conclude that survival worsens when the time between patient detection 
and seeking treatment is increased. The study is limited in that authors provide no rationale for 
choosing the date range of 1991 – 1996. It must be noted that data were old when the research 
was published in 2007. There is also no elaboration made on sample coverage and 
completeness of information available in the cancer registry data which was used for extraction.  
Smithers et al (2010) presented a secondary analysis of data collected for the larger Australian 
Cancer Study. This study began with a sample of 3273, but many of these subjects were either 
non contactable, or had died before the study took place. The strength of this study lies in the 
pre validated questionnaires used to elicit information on patient symptoms and presentation. 
However, the total sample was skewed towards survivors and earlier stage presenters. Of 1100 
subjects, only 831 had a recorded presentation and symptom history. The authors identify 
staging information was only available for 7% of patient records, but it is unclear whether this 
is 7% of the full cohort of 1100, or the 831 with recorded full data. The authors apply a range 
of cross data analyses to generate TNM staging, generating a figure of 50% of the cohort with 
staged data. With this, they draw the conclusion that most patients with GOC will present with 
late stage disease. All of the American studies (Hashemi et al 2009, Schlansky, 2006 and Gibbs, 
2007) are extremely useful, but their generalisability is hampered by their single centre status 
and therefore localised sampling.  
The study by Wang et al (2008), offered a comparative analysis of TNM stage I and II 
diagnosed patients, with TNM stage III and IV to compare delay intervals and their impact on 
survival. Using similar timeframes as Subasinghe et al (2010) they conclude that symptomatic 
patients generally wait on average 2-3 months before seeking assistance and that those who 
present earlier, present with smaller and more localised tumours. They acknowledge the 
limitations of patient recall and, rarely, are they able to offer a dataset with complete TNM 
records.  
Studies presenting information on the treatment interval  
Treatment interval relates to the interval between diagnosis and treatment and involves service 
level delays. Kotz et al (2006) presented a study to identify whether delays between diagnosis 
and surgery may have an impact on survival outcome. Data on 800 patients presenting to a 
single centre between the years 1995 and 2000 were analysed to assess whether delays between 
diagnosis and surgery effected survival outcomes. This study found the time taken between 
histological diagnosis, clinical decision-making and rationalising interventions through 
multidisciplinary team discussions, improves survival outcomes. Kötz et al., (2006) reiterate 
the importance of undertaking multidisciplinary deliberation on treatment strategies and found 
that clinically considered interventions receive more favourable outcomes. This is supported 
in other studies which addressed the total delay interval (Grotenhuis et al., 2010).  
Discussion  
This literature review identifies the patient interval as the most crucial factor for engaging in 
preventive measures to encourage earlier diagnosis. Most patients present at too late a stage for 
curation of gastroesophageal cancer. This supports the stance by the UK government and the 
cancer research (UK) strategy NAEDI (national awareness for early detection and 
intervention). Encouraging earlier diagnosis is essential to improving cancer survival (Hiom 
2015, Neal et al, 2015). A survey of GPs in Scotland published in 2009 (Baughan et al, 2009) 
identified a disparity in referrals which was dependent on tumour type. General Practitioners 
(GPs) referred potential breast and skin cancers far more rapidly than other cancers, including 
those of the upper gastroesophageal, prostate and lung. Kotz et al (2006) identified that GPs 
were more likely to refer males than females for investigations of suspected GOC, suggesting 
females had a higher propensity to system delay. Whereas Macleod et al (2009) and McDonald 
et al (2006) identified males and females exhibited similar wait times to visit a GP with 
suspected symptoms.  
Mcleoud et al (2009) investigated the factors which caused delays in presentation and referrals. 
Generally, these related to clinical factors such as the severity of symptoms, appropriate 
awareness and interpretation of symptoms, emotional status of the patient and any support 
networks they had. Delays in doctor and system levels were attributed to demographic 
attributes of patients, how they presented and provided histories and how practitioners 
responded to cues. McDonald et al (2006) undertook a systematic review of evidence dated 
from 1970 to 2003, to reveal which factors may be associated with delays in diagnosis of upper 
gastrointestinal cancers. The authors identified the main patient related factors associated with 
advanced presenting GOC included low socioeconomic status, non-white ethnicity, presence 
of pain or bleeding and any symptoms which had effected general functional status. The main 
system related factors to delays in diagnosis related to initial misdiagnosis of common 
symptoms and the authors surmised that older males from lower socioeconomic groups were 
less likely to receive faster referrals. These factors were also evident in the findings of this 
literature review, which also revealed common attributes of GOC sufferers.  
There are several behaviourally modifiable risk factors which may be associated with GOC 
presentation. The cancer has been previously linked with smoking, obesity and alcohol misuse 
(Abdullah et al., 2010, Macdonald et al, 2006, Parkin, 2011). Some studies link a lower 
socioeconomic status with the diagnosis (Macleod et al., 2009; Abdullah et al., 2010). Though 
this is contested in Coupland et al’s (2012) study. These authors undertook further evaluation 
on the cancer site and revealed lower socioeconomic status was more prevalent only in those 
with upper and mid oesophageal tumours. Many studies report socioeconomic deprivation as 
an attribute to GOC diagnosis, but these studies are based on limited analysis of site of 
diagnosis (Abdullah et al, 2010, Bus, 2014, Baughan et al, 2009, Mao, 2011). Akram et al, 
(2014) identified living in a rural area has been linked to GOC incidence, but this may reflect 
limited access to services. Many studies link rurality with environmental factors and studies 
into these are ongoing (Mao, 2011, Zhang, 2013, Mohebbi et al, 2011, Aragones et al , 2007).  
All studies in this review linked advanced presentation and delays with worse outcomes. The 
Royal College of Surgeons’ (RCOS) National Oesophagogstric cancer audit (2014) revealed 
that when patients were diagnosed through an emergency hospital admissions, they had 
extremely poor survival outcomes.  
The problem with the patient detecting a potential cancer, is that GOC has a very insidious 
onset and clinical signs may not be clinically detectable until the tumour has reached extensive 
infiltration (Di Pietro, 2013, Jayasekera, 2012, Lambert, 2012, Yang, 2012). The usual clinical 
signs are dyspepsia, dysphagia, nausea and vomiting, weight loss, or gastrointestinal bleeding 
(Wolf et al., 2012). Many papers identify the presence of ‘alarm’ signals caused patients to 
seek health advice more rapidly (Hashemi et al., 2009; Gibbs et al., 2007; Akram et al., 2014). 
Symptoms of weight loss and pain were linked with reduced survival outcomes, but these 
symptoms were key to patients seeking help (Macdonald et al., 2006; Schlansky et al., 2006; 
Macleod et al., 2009; Wang et al., 2008). However, cachexia – the dramatic loss of weight with 
cancers – tends to signify the tumour is at advanced stage (Dhanapal et al, 2011).  
Much of the evidence on presentation of GOC relies on retrospective cohort studies. Of the 12 
papers, 4 were retrospective analysis of existing datasets and these are reliant on country 
specific definitions of timescales. This literature review evaluated geographically diverse 
studies and these need to be considered in context. In China, for example, patients are allowed 
to present directly to the specialist hospital, whereas in the UK, GPs are used as gatekeepers 
and this may cause system delays.  
Public funding and access to healthcare services also has an impact on patient presentation. 
The UK offers a free national health system to the total population, whereas the United States, 
for example, uses health insurance and a private health system to enable basic or advanced 
level access to health-related services. Statistics from each country depend on how patients 
navigate their journey towards diagnosis. Data will subsequently be skewed by patient’s 
socioeconomic status, access to services and by healthcare funding systems.  
Different health systems may not be accurate to capture and record all patient data which is 
relevant to the underlying condition. This was evident in (Baughan et al., 2009) study, where 
disparities in data collection across health boards resulted in delayed analysis of the first year 
of results. The UK had similar issues. They retrieved data from 99% of individual trusts across 
England and Scotland, but Wales did not have sufficient data to complete the national 2013 
GOC audit (AUGS, 2013). Even with hospital episode statistics, the audit could still only claim 
an overall case ascertainment rate for newly diagnosed cancers, to an 85% accuracy (AUGS, 
2013).  
This review revealed that the majority of studies identified patient interval as most crucial to 
earlier diagnosis. However, the evidence presented is based on disparate measurements of 
timescales. For example, Kotz et al (2006) identifies the date of endoscopic biopsy as the date 
of diagnosis and date of death as the end-point, whereas Gibbs used the date of histlogical 
confirmation. Others did not identify how this was defined (Coupland et al, 2012, 
Alimoghaddam, 2014). There was also a range of different diagnostic criteria on which to 
evaluate survival. Even this was inconsistent – as many studies identified a significant lack of 
staging data, or presented results for portions of the cohorts under evaluation. This lack of data 
consistency directly affects underlying quality of the evidence (Weller et al, 2012, Liberati et 
al, 2009).  
There was also a lack of clarity on how and when staging took place. Both Alimoghaddam et 
al (2014) and Subasinghe and Samarasekera's (2010) studies identified missing TNM staging 
data Abdullah et al, (2010) reported a 100% data yield, but did not identify how or when staging 
was undertaken. This was also the case in studies by (Schlansky et al (2006) and Grotenhuis et 
al (2010). The UK Oesophagogastric Audit reported data were missing in 2819 patients (Royal 
College of Surgeons, 2014). These variations in the processes of measurement severely 
threaten internal validity and prevents meta analysis.  
Reliance on the degree of tumour proliferation as a measure of how long the cancer has been 
in situ depends on how metabolically active the tumour is. Subasinghe & Samarasekera's study 
(2010) identify that some tumours may have been present for up to ten years before the patient 
presents and with little or no suggestive symptoms. Yet Dutta et al (2012) describe a ‘doubling 
time’ where extremely metabolically active gastroesophageal tumours can grow and spread 
extensively. In these cases, early diagnosis and rapid removal is essential to a more favourable 
outcome. These factors will affect the findings of this literature review, which relied heavily 
on evidence generated from survival studies.  
Throughout the patient journey there are many factors affecting presentation. The patient must 
suspect there is a problem, the GP must pick up on diagnostic cues, referring appropriately and 
healthcare systems must run effectively to instigate rapid diagnosis and treatment.  
The most crucial period – the ‘patient interval’ is measured from the date the patient first 
noticed a symptom, to the date they presented to their GP (Weller 2012). However, there is a 
significant disparity relating to ‘date of first symptom’. It cannot merely be assumed that 
patients will detect a set of symptoms and will then present to health services to be diagnosed 
with GOC. There are specific symptoms of GOC presentation, (alarm signals) which are 
present in almost 50% of cases (Thrift et al., 2013; Wallace et al., 2001; Fransen et al., 2004). 
However, by the time the patient has symptomatic presentation, the tumour may be far too 
advanced for curative surgery (Fransen et al., 2004; Jones et al., 2007) 
Patients may present with just one sign of GOC (for example, with ‘pain’) and subsequently 
receive analgesia or health related advice. They may then re-present at a different time, with 
the alarm signals resulting in referral and subsequent diagnosis. The time taken for either the 
patient or the referral centre to ‘notice’ GOC related symptoms and seek further assistance, is 
subject to recall bias from all parties involved. Patients may be poor historians, they may not 
identify the full extent of the complaint. Any study investigating delays in the journey attributed 
to when a patient or a referrer ‘noticed’ original symptoms needs to be thoroughly scrutinised. 
The operational definitions underpinning this type of research require objective consideration. 
This review used evidence from several retrospective case note analyses and findings are 
dependent on how ‘well’ the original assessment was documented. Any reports on when 
patients ‘noticed’ signs can only be seen as subjective, unless symptoms occurred within days, 
minutes or hours before presentation. The evidence recording ‘time from noticing a symptom, 
to time to diagnosis or cure’ has a significant potential bias.  
This literature review also revealed the issue that gastroesophageal cancers tend to be 
overlooked in the mainstay of literature. Baughan’s (2009) study identified 600 cases of 
oesophageal cancer, but only reported outcomes for the more common breast, colorectal lung 
and prostate cancers, rather than gastroesophageal cancer and this is common in many cancer 
research articles. The significant disparity in focussing on the less common cancers is evident.  
Gastroesophageal cancer patients die early, therefore, follow up is difficult. As a result, this 
cancer is subject to survivor bias, because patient data are skewed by early subject demise.  
Many papers on cancer survival report a 1, 3 or 5 year outcome. However, most GOC diagnoses 
result in death before two years (Kotz 2006). This affects the data and findings significantly 
and misses the large number of GOC subjects who die within the first 6 or 8 months. A 
reclassification of diagnostic criteria would allow for this skew in GOC survival.  
Limitations 
Gastroesophageal cancer is prevalent across the globe, but more prevalent in middle and far 
Eastern countries, where English is not the primary language. This means there may be 
evidence published in other languages which was not identified in this review. As identified in 
the discussion, the range of different timescales and nomenclature applied in cancer research 
have an impact on results. To identify when a patient actually detected their first symptoms is 
hampered by several confounding factors. The patient journey through many different 
healthcare systems is also complex. How patients present in China may differ significantly, to 
how they present in the US, or UK for example.  
Other factors which have an impact on presentation and survival in gastroesophageal cancer 
are the underlying aetiology, the cancer site, the patient attributes and comorbidities. Most of 
these patients are elderly, so the presence of several other conditions and illnesses is fairly 
common in this cancer.  
Conclusion  
This review of GOC specific evidence identified that the patient interval is the most crucial 
period to encourage earlier presentation. It also highlighted disparate processes of measurement 
and sampling in cancer research articles. The incidence of gastroesophageal cancer is 
increasing across the globe, yet survival remains poor. However, there is a significant lack of 
focus on this cancer in the literature. Further research is essential to evaluate factors which 
potentially cause unnecessary delays in the diagnostic journey. Potential sufferers of this cancer 
need to be encouraged to seek medical attention as the patient interval is the most crucial to 
survival. For this, community level interventions are required to raise awareness of the signs 
and symptoms of this cancer.  
 
 
 
  
References 
Abdullah, M., Karim, A.A. & Goh, K. (2010) Late presentation of esophageal cancer: 
observations in a multiracial South-East Asian population. Journal of Digestive Diseases, 11 
(1), 28-33.  
ABDULLAH, M., KARIM, A.A. & Khean-Lee, G.O.H. (2010) Late presentation of 
esophageal cancer: Observations in a multiracial South–East Asian population. Journal of 
Digestive Diseases, 11 (1), 28-33.  
Adair, T., Hoy, D., Dettrick, Z. & Lopez, A., D. (2011) Trends in oral, pharyngeal and 
oesophageal cancer mortality in Australia: the comparative importance of tobacco, alcohol 
and other risk factors. Australian & New Zealand Journal of Public Health, 35 (3), 212-219.  
Akram, M., Siddiqui, S.A. & Karimi, A.M. (2014) Patient Related Factors Associated with 
Delayed Reporting in Oral Cavity and Oropharyngeal Cancer. International Journal of 
Preventive Medicine, 5 (7), 915-919.  
Alimoghaddam, K., Jalali, A., Aliabadi, L.S., Ghaffari, F., Maheri, R., Eini, E., 
Mashhadireza, M., Mousavi, S.A., Bahar, B., Jahani, M. & Ghavamzadeh, A. (2014) The 
outcomes of esophageal and gastric cancer treatments in a retrospective study, single center 
experience. International Journal of Hematology-Oncology and Stem Cell Research, 8 (2), 9-
13.  
Allum, W.H., Griffith, S.M., Watson, A. & Colin-jones, D. (2002) Guidelines for the 
management of oesophageal and gastric cancer. GUT, 50 (5), v1-v23.  
Aragones, N., Ramis, R., Pollan, M., Perez-Gomez, B., Gomez-Barrosso, D., Lope, V., 
Boldo, E.i., Garcia-Perez, J., Lopez-Abente, G. (2007) Oesophageal cancer mortality in Spain 
- A spatial analysis Bioned Central Cancer 7 (3) available at 
http;//www.biomedcentral.com/1471-2407/7/3 
Baughan, P., O'Neill, B. & Fletcher, E. (2009) Auditing the diagnosis of cancer in primary 
care: the experience in Scotland. British Journal of Cancer, 101 S87-S91.  
Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research 
in Psychology, 3(2), 77-101. 
Coupland, V.H., Allum, W., Blazeby, J.M., Mendall, M.A., Hardwick, R.H., Linklater, K.M., 
Moller, H. & Davies, E.A. (2012) Incidence and survival of oesophageal and gastric cancer in 
England between 1998 and 2007, a population-based study. BMC Cancer, 12 11.  
Chadwick, G., Groene, O., Cromwell, D., Hardwick, R.H., Riley, S., Crosby, T.D.L. and 
Greenaway, K., (2013),  
The National Oesophago-Gastric Cancer Audit London, Health and Social Care Information 
Centre.  
Crowe, M., & Sheppard, L. (2011). A review of critical appraisal tools. Journal of Clinical 
Epidemiology, 64(1), 79-89 
Dixon-Woods, M., Bonas, S., Booth, A., Jones, D., Miller, T., & Sutton, A. (2006) How can 
systematic reviews incorporate qualitative research? A critical perspective. Qualitative 
Research, 6, 27-44. 
Dutta, S., Going, J.J., Crumley, A.B., Mohammed, Z., Orange, C., Edwards, J., Fullarton, 
G.M., Horgan, P.G. & McMillan, D.C. (2012) The relationship between tumour necrosis, 
tumour proliferation, local and systemic inflammation, microvessel density and survival in 
patients undergoing potentially curative resection of oesophageal adenocarcinoma. British 
Journal of Cancer, 106 (4), 702-710.  
Fransen, G.A.J., Janssen, M.J.R., Muris, J.W., Laheij, R.J.F. & Jansen J.B.M.J. (2004) Meta 
analysis : The diagnostic value of alarm symptoms for upper gastrointestinal malignancy. 
Alimentary Pharmacology & Therapeutics, 20 1045-1052.  
Gibbs, J.F., Rajput, A., Chadha, K.S., Douglas, W.G., Hill, H., Nwogu, C., Nava, H.R. & 
Sabel, M.S. (2007) The changing profile of esophageal cancer presentation and its 
implication for diagnosis. Journal of the National Medical Association, 99 (6), 620-626.  
Grotenhuis, B.A., Van Hagen, P., Wijnhoven, B.P.L., Spaander, M.C.W., Tilanus, H.W. & 
Van Lanschot, Jan J. B. (2010) Delay in Diagnostic Workup and Treatment of Esophageal 
Cancer. Journal of Gastrointestinal Surgery, 14 (3), 476-483.  
Hashemi, N., Loren, D., DiMarino, A.J. & Cohen, S. (2009) Presentation and prognosis of 
esophageal adenocarcinoma in patients below age 50. Digestive Diseases and Sciences, 54 
(8), 1708-1712.  
Hawker, S., Payne, S., Kerr, C., Hardey, M. & Powell, J. (2002) Appraising the evidence: 
reviewing disparate data systematically. Qualitative Health Research, 12 (9), 1284-1299.  
JBI. (2014). Joanna Briggs Institute Reviewers’ Manual 2014. Methodology for JBI Mixed 
Methods Systematic Reviews. Adelaide: JBI. 
Jones, R., Latinovic, R., Charlton, J. & Gulliford, M.C. (2007) Alarm symptoms in early 
diagnosis of cancer in primary care: cohort study using General Practice Research Database. 
BMJ: British Medical Journal (International Edition), 334 (7602), 1040-1044.  
Kötz, B.S., Croft, S. & Ferry, D.R. (2006) Do delays between diagnosis and surgery in 
resectable oesophageal cancer affect survival? a study based on West Midlands cancer 
registration data. British Journal of Cancer, 95 (7), 835-840.  
Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gotzsche, P.C., Ioannidis, J.P., Clarke, 
M., Devereaux, P.J., Kleijnen, J. & Moher, D. (2009) The PRISMA statement for reporting 
systematic reviews and meta-analyses of studies that evaluate health care interventions: 
explanation and elaboration. Journal of Clinical Epidemiology, 62 (10), e1-34.  
Macdonald, S., Macleod, U., Campbell, N.C., Weller, D. & Mitchell, E. (2006) Systematic 
review of factors influencing patient and practitioner delay in diagnosis of upper 
gastrointestinal cancer. British Journal of Cancer, 94 (9), 1272-1280.  
Macleod, U., Mitchell, E.D., Burgess, C., Macdonald, S. & Ramirez, A.J. (2009) Risk factors 
for delayed presentation and referral of symptomatic cancer: evidence for common cancers. 
British Journal of Cancer, 101 Suppl 2 S92-S101.  
Mao, W.M., Zheng, W.H., Ling, Z.Q. (2010) Epidemiologic risk factors for gastroesophageal 
cancer development Asian Pacific Journal for Cancer Prevention 12 (10) 146 1-6 
Medical research Council (2002) Surgery with or without preoperative chemotherapy in 
oesophageal cancer; a randomised controlled trial. Lancet, 359 1727-1733.  
Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. (2009) Preferred reporting items for 
systematic reviews and meta analyses : the PRISMA statement. PLoS Med, 6 (6), .  
Moher, D., Altman, D.G., Liberati, A. & Tetzlaff, J. (2011) PRISMA statement. 
Epidemiology (Cambridge, Mass.), 22 (1), 128; author reply 128.  
Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G. & PRISMA Group (2010) Preferred 
reporting items for systematic reviews and meta-analyses: the PRISMA statement. 
International Journal of Surgery (London, England), 8 (5), 336-341.  
Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., 
Stewart, L.A. & PRISMA-P Group (2015) Preferred reporting items for systematic review 
and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews, 4 (1), 1-4053-
4-1.  
Mohiebbi, M., Wolfe, R., Jolley, D., Forbes, A., Mahmoodi, M., Burton, R.C. (2011) The 
spatial distribution of oesophageaL AND GASTRIC CANCER IN THE Caspian Region of 
Iran, An ecological analysis of diet and socioeconomic influences. International journal of 
health Geographics 10 (13)  
National Institute for Health and Clinical Excellence, (2005), Referral Guidelines for 
suspected cancer. Clinical Guideline 27, UK, NIHCE.  
Neal, R.D., Tharmanathan, P., France, B., Din, N.U., Cotton, S., Fallon-Ferguson, J., 
Hamilton, W., Hendry, A., Hendry, M., Lewis, R., Macleod, U., Mitchell, E.D., Pickett, M., 
Rai, T., Shaw, K., Stuart, N., Torring, M.L., Wilkinson, C., Williams, B., Williams, N. & 
Emery, J. (2015) Is increased time to diagnosis and treatment in symptomatic cancer 
associated with poorer outcomes? Systematic review. British Journal of Cancer, .  
NHS The Information Centre, (2008), National Oesophagogastric Cancer Audit. First 
Annual report, The NHS Information centre.  
Nuting, C.M., Robinson, M. & Birchall, M. (2008) Survival from Laryngeal cancer in 
England and Wales up to 2001. British Journal of Cancer, 99 (1), s38-s39.  
Office for National Statistics, (2005), Cancer Statistics Registrations: Registrations of cancer 
diagnosed in 2005. 36, ONS.  
Orengo, M.A., Casella, C., Fontana, V., Filiberti, R., Conio, M., Rosso, S., Tumino, R., 
Crosignani, P., De Lisi, V., Falcini, F. & Vercelli, M. (2006) Trends in incidence rates of 
oesophagus and gastric cancer in Italy by subsite and histology, 1986-1997. European 
Journal of Gastroenterology & Hepatology, 18 (7), 739-746.  
 
 
Parkin, D.M., Boyd, L., Walker, L.C. (2011) The fraction of cancer attributable to lifestyle 
and environmental factors in the UK in 2010. British Journal of Cancer. 105(S2) S77-S81. 
 
Read more at http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-
by-cancer-type/oesophageal-cancer/risk-factors#gcFrZACc3SJSFYmW.99 
Pluye, P., Gagnon, M., Griffiths, F.., Johnson-Lafleur, J. (2009) A scoring system for 
appraising mixed methods research and concomitantly appraising qualitative, quantitative and 
mixed methods primary studies in mixed studies reviews International Journal of Nursing 
Studies 46. 529–546 
Pluye, P., Robert, E., Cargo, M., Bartlett, G., O’Cathain, A., Griffiths, F., Boardman, F., 
Gagnon, M.P., & Rousseau, M.C. (2011). Proposal: A mixed methods appraisal tool for 
systematic mixed studies reviews. Department of Family Medicine, McGill University, 
Montreal, Canada. Available at from http://mixedmethodsappraisaltoolpublic.pbworks.com. 
Archived by WebCite® at http://www.webcitation.org/5tTRTc9yJ accessed 031016 
Pluye, P. & Hong, Q.N. (2014). Combining the power of stories and the power of numbers: 
Mixed Methods Research and Mixed Studies Reviews. Annual Review of Public Health, 35, 
29-45. 
Richards, M.A. (2009a) The size of the prize for earlier diagnosis of cancer in England. 
British Journal of Cancer, 101 Suppl 2 S125-9.  
Richards, M.A. (2009b) The size of the prize for earlier diagnosis of cancer in England. 
British Journal of Cancer, 101 Suppl 2 S125-9.  
Royal College of Surgeons, (2014), National Oesophagogstric Cancer Audit progress report 
2014. UK, Royal College of Surgeons of England.  
Schlansky, B., Dimarino, A.J., J., Loren, D., Infantolino, A., Kowalski, T. & Cohen, S. 
(2006) A survey of oesophageal cancer: pathology, stage and clinical presentation. 
Alimentary Pharmacology & Therapeutics, 23 (5), 587-593.  
Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., 
Stewart, L.A. & PRISMA-P Group (2015) Preferred reporting items for systematic review 
and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clinical 
Research Ed.), 349 g7647.  
Sloggett, A., Young, H. & Grundy, E. (2007) The association of cancer survival with four 
socioeconomic indicators : a longitudinal study of the older population of England and Wales 
1981 - 2000. BMC Cancer, 7 (20), .  
Smithers, B.M., Fahey, P.P., Corish, T., Gotley, D.C., Falk, G.L., Smith, G.S., Kiroff, G.K., 
Clouston, A.D., Watson, D.I. & Whiteman, D.C. (2010) Symptoms, investigations and 
management of patients with cancer of the oesophagus and gastro-oesophageal junction in 
Australia. The Medical Journal of Australia, 193 (10), 572-577.  
Subasinghe, D. & Samarasekera, D.N. (2010) Delay in the diagnosis of esophageal 
carcinoma: experience of a single unit from a developing country. Indian Journal of Cancer, 
47 (2), 151-155.  
Thrift, A.P., Kendall, B.J., Pandeya, N. & Whiteman, D.C. (2013) A Model to Determine 
Absolute Risk for Esophageal Adenocarcinoma. Clinical Gastroenterology and Hepatology, 
11 (2), 138-144.e2.  
Wallace, M.B., Durkalski, V.L. & Vaughan, J. (2001) Age and alarm signals do not predict 
endoscopic findings among patients with dyspepsia : A multicentre database study. Gut, 49 
29-34.  
Wang, J., Liu, F., Gao, H., Wei, W., Zhang, X., Liang, Y. & Cheng, Y. (2008) The symptom-
to-treatment delay and stage at the time of treatment in cancer of esophagus. Japanese 
Journal of Clinical Oncology, 38 (2), 87-91.  
Weller, D., Vedsted, P., Rubin, G., Walter, F.M., Emery, J., Scott, S., Campbell, C. andersen, 
R.S., Hamilton, W., Olesen, F., Rose, P., Nafees, S., van Rijswijk, E., Hiom, S., Muth, C., 
Beyer, M. & Neal, R.D. (2012) The Aarhus statement: improving design and reporting of 
studies on early cancer diagnosis. British Journal of Cancer, 106 (7), 1262-1267.  
Zheng, S., Vuitton, L., Sheyhidin, I., Vuitton, D.A., Zhang, Y. & Lu, X. (2010) Northwestern 
China: a place to learn more on oesophageal cancer. Part one: behavioural and environmental 
risk factors. European Journal of Gastroenterology & Hepatology, 22 (8), 917-925.  
Zhang, Y. (2013) Epidemiology of esophageal cancer World Journal of gastroenterology 19 
(34) 5598-606 
 
